Downregulation of microRNA-95-3p suppresses cell growth of osteosarcoma via CDKN1A/p21 expression

Zhao,Xin; Yang,Yukai; Xu,Jianting; Luo,Yang; Xin,Ying; Wang,Yanbing

doi:10.3892/or.2017.6065

Downregulation of microRNA-95-3p suppresses cell growth of osteosarcoma via CDKN1A/p21 expression

Authors:
- Xin Zhao
- Yukai Yang
- Jianting Xu
- Yang Luo
- Ying Xin
- Yanbing Wang
View Affiliations

Affiliations: Department of Orthopedics, The Second Hospital of Jilin University, Changchun, Jilin, P.R. China, Department of Orthopedics, Tongliao Kezuozhongqi People's Hospital, Neimenggu, P.R. China, Cancer Center, The First Hospital of Jilin University, Changchun, Jilin, P.R. China, Department of Orthopaedics, General Hospital of Chinese PLA, Beijing, P.R. China, Key Laboratory of Pathobiology, Ministry of Education, Jilin University, Changchun, Jilin, P.R. China
Published online on: November 1, 2017 https://doi.org/10.3892/or.2017.6065
Pages: 289-297

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The purpose of the present study was to examine the function of microRNA-95-3p on cell growth of osteosarcoma and to investigate its mechanism. Compared to healthy controls, the serum expression of microRNA-95-3p was effectively upregulated in patients with osteosarcoma. MicroRNA-95-3p expression in patients with osteosarcoma had significant association with clinical stage. Downregulation of microRNA-95-3p expression suppressed cell growth, induced apoptosis, increased caspase-3 and caspase-9 activities and Bax/Bcl-2 protein expression in osteosarcoma cells. The anticancer effects of microRNA-95-3p on cell growth of osteosarcoma cell suppressed TGF-β and p-Smad2 protein expression, induced p21 protein expression and suppressed cyclin D1 protein expression in osteosarcoma cells. Whereas, overexpression of microRNA-95-3p increased cell growth, and inhibited apoptosis of osteosarcoma cells through TGF-β/CDKN1A/p21/cyclin D1 expression. After promotion of TGF-β, the anticancer effects of microRNA-95-3p were effectively reversed in osteosarcoma cells. Taken together, our results demonstrate that downregulation of microRNA-95-3p suppresses cell growth of osteosarcoma via CDKN1A/p21 expression.

View Figures

View References

1	Ebb D, Meyers P, Grier H, Bernstein M, Gorlick R, Lipshultz SE, Krailo M, Devidas M, Barkauskas DA, Siegal GP, et al: Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: A report from the children's oncology group. J Clin Oncol. 30:2545–2551. 2012. View Article : Google Scholar : PubMed/NCBI
2	Li J, Guo Z, Wang Z, Fan H and Fu J: Does microwave ablation of the tumor edge allow for joint-sparing surgery in patients with osteosarcoma of the proximal tibia? Clin Orthop Relat Res. 473:3204–3211. 2015. View Article : Google Scholar : PubMed/NCBI
3	Bajpai J, Gamanagatti S, Sharma MC, Kumar R, Vishnubhatla S, Khan SA, Rastogi S, Malhotra A and Bakhshi S: Noninvasive imaging surrogate of angiogenesis in osteosarcoma. Pediatr Blood Cancer. 54:526–531. 2010.PubMed/NCBI
4	Bacci G, Ferrari S, Longhi A, Picci P, Mercuri M, Alvegard TA, Saeter G, Donati D, Manfrini M, Lari S, et al Italian Sarcoma Group/Scandinavian Sarcoma Group, : High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: Preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study. J Chemother. 14:198–206. 2002. View Article : Google Scholar : PubMed/NCBI
5	Wang X, Ning Y, Yang L, Liu H, Wu C, Wang S and Guo X: Diagnostic value of circulating microRNAs for osteosarcoma in Asian populations: A meta-analysis. Clin Exp Med. 17:175–183. 2017. View Article : Google Scholar : PubMed/NCBI
6	Chen R, Li X, He B and Hu W: MicroRNA-410 regulates autophagy-related gene ATG16L1 expression and enhances chemosensitivity via autophagy inhibition in osteosarcoma. Mol Med Rep. 15:1326–1334. 2017. View Article : Google Scholar : PubMed/NCBI
7	Shang Y, Wang LQ, Guo QY and Shi TL: MicroRNA-196a overexpression promotes cell proliferation and inhibits cell apoptosis through PTEN/Akt/FOXO1 pathway. Int J Clin Exp Pathol. 8:2461–2472. 2015.PubMed/NCBI
8	Han K, Zhou Y, Gan ZH, Qi WX, Zhang JJ, Fen T, Meng W, Jiang L, Shen Z and Min DL: p21-activated kinase 7 is an oncogene in human osteosarcoma. Cell Biol Int. 38:1394–1402. 2014. View Article : Google Scholar : PubMed/NCBI
9	Zhang X, Ma W, Cui J, Yao H, Zhou H, Ge Y, Xiao L, Hu X, Liu BH, Yang J, et al: Regulation of p21 by TWIST2 contributes to its tumor-suppressor function in human acute myeloid leukemia. Oncogene. 34:3000–3010. 2015. View Article : Google Scholar : PubMed/NCBI
10	Pappo AS, Vassal G, Crowley JJ, Bolejack V, Hogendoorn PC, Chugh R, Ladanyi M, Grippo JF, Dall G, Staddon AP, et al: A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: Results of a Sarcoma Alliance for Research Through Collaboration study. Cancer. 120:2448–2456. 2014. View Article : Google Scholar : PubMed/NCBI
11	Kudawara I, Aoki Y, Ueda T, Araki N, Naka N, Nakanishi H, Matsumine A, Ieguchi M, Mori S, Myoui A, et al: Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: A phase II trial in Japan. J Chemother. 25:41–48. 2013. View Article : Google Scholar : PubMed/NCBI
12	Grignani G, Palmerini E, Ferraresi V, D'Ambrosio L, Bertulli R, Asaftei SD, Tamburini A, Pignochino Y, Sangiolo D, Marchesi E, et al Italian Sarcoma Group, : Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: A non-randomised phase 2 clinical trial. Lancet Oncol. 16:98–107. 2015. View Article : Google Scholar : PubMed/NCBI
13	den Hengst WA, Hendriks JM, Balduyck B, Rodrigus I, Vermorken JB, Lardon F, Versteegh MI, Braun J, Gelderblom H, Schramel FM, et al: Phase II multicenter clinical trial of pulmonary metastasectomy and isolated lung perfusion with melphalan in patients with resectable lung metastases. J Thorac Oncol. 9:1547–1553. 2014. View Article : Google Scholar : PubMed/NCBI
14	Fan B, Jiao BH, Fan FS, Lu SK, Song J, Guo CY, Yang JK and Yang L: Downregulation of miR-95-3p inhibits proliferation, and invasion promoting apoptosis of glioma cells by targeting CELF2. Int J Oncol. 47:1025–1033. 2015. View Article : Google Scholar : PubMed/NCBI
15	Sampson VB, Yoo S, Kumar A, Vetter NS and Kolb EA: MicroRNAs and potential targets in osteosarcoma: Review. Front Pediatr. 3:692015. View Article : Google Scholar : PubMed/NCBI
16	Wang Z, He R, Xia H, Wei YU and Wu S: MicroRNA-101 has a suppressive role in osteosarcoma cells through the targeting of c-FOS. Exp Ther Med. 11:1293–1299. 2016. View Article : Google Scholar : PubMed/NCBI
17	Xu M, Xie Y, Sheng W, Miao J and Yang J: Adenovirus-mediated ING4 gene transfer in osteosarcoma suppresses tumor growth via induction of apoptosis and inhibition of tumor angiogenesis. Technol Cancer Res Treat. 14:369–378. 2015. View Article : Google Scholar : PubMed/NCBI
18	Yong ST and Wang XF: A novel, non-apoptotic role for Scythe/BAT3: A functional switch between the pro- and anti-proliferative roles of p21 during the cell cycle. PLoS One. 7:e380852012. View Article : Google Scholar : PubMed/NCBI
19	Ye J, Yao Y, Song Q, Li S, Hu Z, Yu Y, Hu C, Da X, Li H, Chen Q, et al: Up-regulation of miR-95-3p in hepatocellular carcinoma promotes tumorigenesis by targeting p21 expression. Sci Rep. 6:340342016. View Article : Google Scholar : PubMed/NCBI
20	Kim BG, Lee JH, Yasuda J, Ryoo HM and Cho JY: Phospho-Smad1 modulation by nedd4 E3 ligase in BMP/TGF-β signaling. J Bone Miner Res. 26:1411–1424. 2011. View Article : Google Scholar : PubMed/NCBI
21	Navid F, Letterio JJ, Yeung CL, Pegtel M and Helman LJ: Autocrine transforming growth factor-beta growth pathway in murine osteosarcoma cell lines associated with inability to affect phosphorylation of retinoblastoma protein. Sarcoma. 4:93–102. 2000. View Article : Google Scholar : PubMed/NCBI
22	Li F, Li S and Cheng T: TGF-β1 promotes osteosarcoma cell migration and invasion through the miR-143-versican pathway. Cell Physiol Biochem. 34:2169–2179. 2014. View Article : Google Scholar : PubMed/NCBI
23	Chow LT: Giant cell rich osteosarcoma revisited-diagnostic criteria and histopathologic patterns, Ki67, CDK4, and MDM2 expression, changes in response to bisphosphonate and denosumab treatment. Virchows Arch. 468:741–755. 2016. View Article : Google Scholar : PubMed/NCBI
24	Benassi MS, Molendini L, Gamberi G, Ragazzini P, Sollazzo MR, Merli M, Asp J, Magagnoli G, Balladelli A, Bertoni F, et al: Alteration of pRb/p16/cdk4 regulation in human osteosarcoma. Int J Cancer. 84:489–493. 1999. View Article : Google Scholar : PubMed/NCBI
25	Zhang C, Zhao Y and Zeng B: Enhanced chemosensitivity by simultaneously inhibiting cell cycle progression and promoting apoptosis of drug-resistant osteosarcoma MG63/DXR cells by targeting cyclin D1 and Bcl-2. Cancer Biomark. 12:155–167. 2012. View Article : Google Scholar : PubMed/NCBI
26	Wang J, Ni J, Yi S, Song D and Ding M: Protein inhibitor of activated STAT xα depresses cyclin D and cyclin D kinase, and contributes to the inhibition of osteosarcoma cell progression. Mol Med Rep. 13:1645–1652. 2016. View Article : Google Scholar : PubMed/NCBI
27	Hwang SJ, Lee HW, Kim HR, Song HJ, Lee DH, Lee H, Shin CH, Joung JG, Kim DH, Joo KM, et al: Overexpression of microRNA-95-3p suppresses brain metastasis of lung adenocarcinoma through downregulation of cyclin D1. Oncotarget. 6:20434–20448. 2015. View Article : Google Scholar : PubMed/NCBI